Eli Lilly reports a reduced rate of hospitalization for coronavirus patients using its antibody treatment

Coronavirus live updates: Eli Lilly begins late-stage trials for antibody drug; Russia plans mass vaccination

In this May 2020 picture offered by Eli Lilly, researchers put together mammalian cells to supply doable COVID-19 antibodies for testing in a laboratory in Indianapolis.

David Morrison | Eli Lilly by way of AP

LONDON — Eli Lilly introduced on Wednesday it had discovered proof of idea information from an interim evaluation of the BLAZE-1 scientific trial that confirmed a reduced rate of hospitalization for coronavirus patients handled with its neutralizing antibody drug.

“These interim data from the BLAZE-1 trial suggest that LY-CoV555, an antibody specifically directed against SARS-CoV-2, has a direct antiviral effect and may reduce COVID-related hospitalizations,” Daniel Skovronsky, Lilly’s chief scientific officer and president of Lilly Research Laboratories, stated in a assertion.

“The results reinforce our conviction that neutralizing antibodies can help in the fight against COVID-19,” Skovronsky stated.

Source link

Be the first to comment

Leave a Reply